Advancing peptides for the treatment of rare endocrine and metabolic disorders

We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.

PROGRAMS

AZP-3601

Our lead clinical candidate is a therapeutic peptide in development as a potential treatment for hypoparathyroidism, a rare endocrine disorder.

AZP-3800

We are testing a series of novel, highly potent, small peptide antagonists of the growth hormone (GH) receptor to select a lead development candidate for treatment of acromegaly.

AZP-38XX Acromegal

AZP-3404

AZP-3404

AZP-3404 is a first-in-class therapeutic peptide that may restore fat and glucose metabolism in the body.

LEADERSHIP

Our management team has the collective and proven expertise necessary to advance its portfolio of therapeutic peptides in the clinic.

Press Releases & Recent News

Amolyt Pharma to Present New Phase 1 Data on AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, and Preclinical Data on AZP-3404 at Upcoming Scientific Conferences

Download a PDF copy of this press release: EN FR New data from all cohorts of Phase 1 Single Ascending …

Read More →
Download a PDF: EN or FR

Amolyt Pharma Presents First Clinical Data for AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021)

Download a PDF copy of this press release: EN FR Data from first 4 cohorts of the single ascending dose …

Read More →
Download a PDF: EN or FR

Join Our Team

We are always looking for talented and driven individuals to join our diverse and collaborative team to help us achieve our mission.

Contact Us

We welcome open and continuous dialogue with all interested parties, including patients, healthcare providers, potential partners and investors.

Scroll to Top